We have shown previously that acute hypoxia downregulates protein kinase G (PKG) expression and activity in ovine fetal pulmonary vessels and pulmonary arterial smooth muscle cells (SMC). Here, we report that acute hypoxia also reduces the expression of leucinezipper-positive MYPT1 (LZ + MYPT1), a subunit of myosin light chain (MLC) phosphatase, in ovine fetal pulmonary arterial SMC. We found that in hypoxia, there is greater interaction between LZ + MYPT1 and RhoA and Rho kinase 1 (ROCK1)/Rho kinase 2 (ROCK2) and decreased interaction between LZ + MYPT1 and PKG, resulting in increased MLC 20 phosphorylation, a higher pMLC 20 /MLC 20 ratio and SMC contraction. In normoxic SMC PKG overexpression,LZ + MYPT1 expression is upregulated while PKG knockdown had an opposite effect. LZ + MYPT1 overexpression enhanced the interaction between PKG and LZ + MYPT1. Overexpression of a mutant LZ -MYPT1 isoform in SMC mimicked the effects of acute hypoxia and decreased pMLC 20 /MLC 20 ratio. Collectively, our data suggest that hypoxia downregulates LZ + MYPT1 expression by suppressing PKG levels, reduces the interaction of LZ + MYPT1 with PKG and promotes LZ + MYPT1 interaction with RhoA or ROCK1/ROCK2, thereby promoting pulmonary arterial SMC contraction.
INTRODUCTION
Acute hypoxia leads to a rapid reversible physiological response of pulmonary vasoconstriction (reviewed in [1] ). Myosin light chain (MLC) phosphorylation is a critical step that leads to activation of myosin ATPase and subsequent smooth muscle cell (SMC) contraction. Myosin light chain 20 (MLC 20 ) is phosphorylated by MLC kinase (MLCK) and de-phosphorylated by MLC phosphatase (MLCP). Although a recent study has shown that MAP kinase phosphorylates MLC independent of MLCK in urinary bladder SMC, [2] MLCK is still considered to be the main enzyme responsible for phosphorylation of MLC 20 and MLC phosphatase is the main enzyme involved in regulation of MLC 20 dephosphorylation and vasodilatation. [3, 4] In general, the contractile state of the SMC re lects the ratio of activities of MLCK/MLCP and pMLC 20 /MLC 20 .
MLCP is a hetero-trimeric protein composed of a catalytic subunit PP1C (see References 5 and 6 for review), a regulatory subunit also known as myosin phosphatase targeting unit (MYPT) and a 20 kD protein of unknown function. Regulatory subunits of the MYPT family are the central targeting proteins thatinteract with a number of other signaling molecules such as protein kinase G (PKG), Rho kinase 1 (ROCK1) and Rho kinase 2 (ROCK2) (reviewed in Reference 7) . There are fourdifferent types of MYPT1 monomers produced endogenously by splicing, i.e. MYPT1 with or without central insert (CI), and both these forms are further spliced with (LZ + MYPT1) or without (LZ -MYPT1) LZ, a leucine zipper at the c-terminal. The speci icity of MLCP is primarily determined by the interaction of PP1cä with the targeting protein MYPT. [8, 9] It has been reported that the sensitivity of smooth muscle to cGMP-induced relaxation correlates with the relative expression of LZ + MYPT1 and LZ -MYPT1 isoforms, as overexpression of LZ + MYPT1 or LZ -MYPT1 isoforms in cultured SMC modulates cGMP-mediated MLC 20 dephosphorylation. [10] [11] [12] Smooth muscle contractility is modulated by the ratio of phosphorylated MLC 20 to unphosphorylated MLC 20 (pMLC 20 /MLC 20 ) , and this ratio is regulated by the relative activities of MLCK/ MLCP. [3, 4] We tested the hypothesis that hypoxia regulates the level of LZ + MYPT1 and LZ -MYPT1 isoforms, and thereby SMC contractility, in cultured ovine fetal pulmonary arterial SMC (FPASMC). We report that hypoxia downregulates the expression of LZ + MYPT1, a predominant isoform in vascular smooth muscle in a PKG-dependent manner, reduces the interaction between LZ + MYPT1 andPKG and promotes its interactions with ROCK1/ROCK2, resulting in increased MLC phosphorylation and SMC contraction.
MATERIALS AND METHODS

Reagents
Trolox [(+)-6-hydroxy-2,5,7,8-tetramethyl-chroman-2carboxylic acid], N-acetyl cysteine (NAC) and all other chemicals (unless otherwise speci ied) were obtained from Sigma-Aldrich (St. Louis, Mo., USA). 8-Bromo-cGMP (8-Br-cGMP) was purchased from Axxora LLC/Biolog Life Science Institute (San Diego, Calif., USA).
Animals
Pregnant ewes carrying single or twin fetuses (140 days of gestation; term being 147 days, either sex) were obtained from Nebeker Ranch in Lancaster, California (altitude 300 m.; arterial PO 2 (PaO 2 ): 102 +2 Torr). After the fetuses were delivered, each ewe was euthanized with T-61 euthanasia solution (Hoechst-Roussel, Somerville, NJ, USA). All procedures and protocols used in the present study were approved by the Animal Research Committees of Loma Linda University, Los Angeles Biomedical Research Institute at Harbor-UCLA and by the University of Illinois at Chicago.
Tissue preparation and cell culture
Fourth-generation pulmonary arteries (outside diameter: 1.5-2.5 mm) were dissected free of parenchyma and kept in ice-cold modi ied Krebs-Ringer bicarbonate buffer (composition in mM: 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 25.0 NaHCO 3 and 11.1 glucose) and primary ovine FPASMC were isolated from pulmonary arteries as described earlier. [13] Cells were maintained in DMEM containing 10% heat-inactivated fetal bovine serumand antibiotics (Invitrogen, Carlsbad, Calif., USA). Primary ovine FPASMC were con irmed to beSMCs by their typical "hill and valley" morphology and by α-smooth muscle actin immuno luorescent staining. Contamination with endothelial cells is ruled out by negative immuno luorescent staining with an anti-von Willebrand factor VIII antibody. All experiments were performed with cells at passages 4-6.
Hypoxia exposure
Subcon luent FPASMC were serum-starved (0.5% serum) for 16 h and then exposed to 4 h of hypoxia or normoxia at 37°C, as previously described. [13] Brie ly, cells were placed in a specialized hypoxia chamber into which a gas mixture of 0% O 2 , 5% CO 2 and balance nitrogen was lowed in at a rate suf icient to keep O 2 concentration within the chamber at 3%. The concentration of O 2 within the chamber was constantly monitored and controlled with an O 2 controller (Model ProOxC, Biospherix, Lacona, NY, USA). [13] The PO 2 in the cell media during hypoxia was 30-40 Torr and during normoxia was 100 Torr. For normoxia experiments, cells were incubated in a humidi ied incubator with a constant supply of 5% CO 2 at 37°C.
siRNA transfection
We used PKG-speci ic small interfering ribonucleic acid (siRNA) to knockdown PKG expression in FPASMC. [13] A nonsilencing oligonucleotide sequence (nonsilencingsiRNA) that does not recognize any known homology to mammalian genes was used as a negative control (Qiagen, Valencia, Calif., USA cat. no. 1022563). FPASMC were transfected with siRNAs using Lipofectamine 2000 reagent (Invitrogen). Fresh medium was added after 6 h of transfection and the cells were further cultured for 24 hbefore exposing them to hypoxia or normoxia for 4 h. PKG1 expression level and activity was determined as described earlier. [13] FPASMC were treated with 210 -4 M Trolox (an ONOOscavenger) or 110 -3 M NAC for 30 min before exposure to 4 h hypoxia.
Transient transfections
To overexpress PKG1, we used the Lenti-X overexpression system (Clontech, Mountain View, Calif., USA) as recommended by the manufacturer. In brief, Lent-X vector containing a full-length PKG1α tagged with green luorescent protein (GFP) was co-transfected along with a Lenti-X HT Packaging Mix into 293 T cell line using Lipofectamine 2000. Lentiviral supernatant produced by the transfected packaging cells was then used to infect FPASMC along with polybrene (4g/mL). FPASMC overexpressing PKG1 were selected by Puromycin (1.5 g/mL). Lentiviral negative control cells were included in all the experiments. After 24 h of transfection, cells were serum-starved overnight before exposure to hypoxia or normoxia for 4 h.
A full-length MYPT1 ( + LZ) construct with all the functional domains in MYPT1 and a MYPT1 ( -LZ) construct lacking the LZ domain, gifts from F.V. Brozowich, [14] were puri ied and their sequence veri ied before use in experiments. Cells weretransfected with MYPT1 + LZ and MYPT -LZconstructs using lipofectamine 2000 (Invitrogen) and subsequently exposed to normoxia. Empty vector, pcDNA3.1, was transfected as a negative control. Transfection ef iciency was analyzed by immunoblot analysis using appropriate antibodies.
Western blot analysis
After each experimental exposure, FPASMC were harvested in RIPA buffer (20 mMTris-HCl-pH 7.5, 150 mMNaCl, 1 mM EDTA, 1 mM EGTA, 1% IGEPAL, 2.5 mM sodium pyrophosphate, 1mM β-glycerophosphate) containing protease and phosphatase inhibitor cocktails (Sigma-Aldrich) and protein concentration was determined using the Bradford protein assay kit (Biorad, Hercules, Calif., USA). Equal amounts of total protein (10-50 μg) from cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresisand blotted onto nitrocellulose membrane and probed with primary antibodies according to the manufacturer's instructions. Horseradish peroxidase (GE Life Sciences, Piscataway, NJ, USA) was used as secondary antibody at concentrations from 1:2,000 to 1:20,000. Immunoreactive bands were detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce , Rockford, Ill). The relative intensities of immunoreactive bands were quanti ied by densitometry using -actin band as a reference. The primary antibodies used for this study include anti-MYPT1, anti-pMYPT1 (Ser 695 ) and anti-MLC 20 (Santa Cruz Biotech, Santa Cruz, Calif.); anti-pMLC 20 (Ser 18 /Ser 19 ) from Cell Signaling, Danvers, Mass., USA; anti-PKG1α and anti--actin antibodies from Calbiochem, San Diego, CA, USA; and MYPT1 monoclonal antibody (BD) and LZ + MYPT1 antibody (custom antibody from Af inity Bioreagent, Rockford, Ill., USA). The amount of PKG-mediated MLCP phosphorylation was determined by measuring phosphorylation of MYPT1 at Ser 695 using pMYPT1Ser 695 antibodies (Santa Cruz Biotechnology, Santa Cruz, Calif., USA). Also, phosphorylation of MLC at Thr 18 /Ser 19 and MLC 20 was evaluated by immunoblotting with the respective antibodies (Santa Cruz Biotechnology).
Immunoprecipitation
Total proteins from FPAMSC were extracted in RIPA buffer after exposure to acute hypoxia or normoxia for 4 h, as described earlier. One microgram of polyclonal anti-RhoA, ROCK 1, ROCK2 or PKG1α antibody was prebound with Ultralink immobilized protein A/G (Pierce) by gentle shaking for 1 h at room temperature. The prebound primary antibody and protein A/G agarose complex was then added to each sample (200 μg protein) and incubated at 4°C overnight. The agarose beads were washed in tris buffered saline (TBS) three-times and boiled in 1x sample buffer (Bio-rad). Western blot analysis was performed as described above.
Statistical analysis
Statistical analysis of the data was performed using a standard two-sample Student's t-test assuming unequal variances of the two data sets and one-way ANOVA for the comparison of multiple experimental groups. Statistical signi icance was determined using a two-tailed distribution and was set at the 5% level (P<0.05).
RESULTS
Hypoxia downregulates PKG and LZ + MYPT1 expression in FPASMC
Cells at 75% confluence were exposed to hypoxia or normoxia for 4 h, cell lysates prepared and separated on acrylamide gels. Membranes were probed with anti-PKG, anti-LZ + MYPT1 or anti-â-actin antibodies. Bands were quantified by densitometry using â-actin as a reference. As shown in Figure 1 , hypoxic exposure significantly decreased (by 20-35%) the expression levels of PKG ( Fig. 1 a and 
PKG Knockdown mimics the effects of acute hypoxia on LZ + MYPT1 expression in FPASMC
Next, we determined whether lower expression levels of PKG would mimic the effects of acute hypoxia on LZ+MYPT1 expression. FPASMC were transfected with siRNA speci ic for PKG (si-PKG) or nonsilencingsiRNA that does not recognize any known homology to mammalian genes. PKG and LZ + MYPT1 expression was analyzed by Western blot analysis. There was a 45-60% decrease in PKG expression in siPKG-transfected cells compared with control cells ( Fig. 2a and b ). There was no signi icant change in the expression level of PKG and LZ+MYPT1 between mocktransfected FPASMC and nonsilencingsiRNA-transfected control cells ( Fig. 2a-d ). PKG knockdown caused decreased LZ + MYPT1 expression ( Fig. 2c and d ). This result suggests that hypoxia downregulates LZ + MYPT1 expression by reducing PKG expression.
Overexpression of PKG abrogates the effect of acute hypoxia on LZ + MYPT1 expression
To determine whether overexpression of PKG can abrogate the effect of acute hypoxia on LZ + MYPT1 expression, a plasmid encoding a full-length PKG1α (PKG-GFP) tagged with a GFP was transfected into FPASMC exposed to normoxia or hypoxia for 4 h and the expression of PKG1á and LZ + MYPT1 was analyzed by immunoblot analysis. Overexpression of PKG1α ( Fig. 3 a and b ) signi icantly increased LZ + MYPT1 expression in normoxic cells and also blocked the inhibitory effects of hypoxia on LZ + MYPT1 expression ( Fig. 3c and d) . These data further support our contention that hypoxia by reducing PKG1á expression suppresses LZ + MYPT1 levels in FPASMC.
Reactive oxygen species, by reducing PKG expression, decrease LZ + MYPT1 levels in hypoxia
Reactive oxygen species (ROS) generated in hypoxia (23, (28) (29) (30) have been shown to play a role in the downregulation of PKG expression. [15] To test whether ROS are directly involved in the downregulation of LZ + MYPT1 expression, FPASMC were pretreated with ROS scavengers, N-acetyl cysteine (NAC) or trolox (scavenger of peroxynitrite) before exposing them to hypoxia. There was no change in the expression level of PKG or LZ + MYPT1 in cells preincubated with trolox or NAC under normoxia ( Fig. 4 ). However, trolox or NAC blocked the downregulation of PKG and LZ + MYPT1 expression by hypoxia ( Fig. 4a-d) .To determine whether loss of LZ + MYPT1 expression in hypoxia-exposed cells is attributable to decreased levels of PKG expression or enhanced levels of ROS production, cells were transfected with PKG-siRNA and then exposed to hypoxia in the presence or absence of troloxor NAC. Under these conditions, trolox or NAC could not restore hypoxia-induced reduction in LZ + MYPT1 expression in PKG-siRNA transfected cells ( Fig. 5a-g) .This result suggests that ROS regulate LZ + MYPT1 expression only indirectly by modulating PKG expression in hypoxia.
Role of PKG and/or ROS in hypoxia-mediated decrease in MLCP activity
To further determine the mechanism for inactivation of MLCP in hypoxia, FPASMC transfected with PKG-siRNA or nonsilencingsiRNA were exposed to hypoxia in the presence and absence of trolox or NAC. Cell extracts were isolated, blotted onto membrane and probed with native MYPT1 or phospho-speci ic (Ser 695 ) MYPT1 antibodies. The We found decreased (two-fold) levels of MYPT1 phosphorylation at Ser 695 in both acute hypoxia ( Fig. 4a-g) and PKG-siRNA transfected cells treated with trolox or NAC ( Fig. 5a-g) , but not in trolox-or NAC-treated cells not transfected with PKG-siRNA ( Fig. 4e and f) . This result suggests that hypoxia inactivates MLCP by decreasing PKGmediated MYPT1 phosphorylation at Ser 695 .
Overexpression of MYPT1 lacking LZ motif (LZ -MYPT1) mimics the effects of hypoxia on PKGmediated LZ + MYPT and MLCP phosphorylation
FPASMC that were transfected with a MYPT1 ( -LZ) construct lacking the leucine zipper showed signi icantly decreased levels of endogenous LZ + MYPT1 in normoxia, similar to the decreased levels following hypoxia (4h). Likewise, there was a signi icantly decreased (50% of control values) level of Ser 695 phosphorylation in MYPT1 in ( -LZ) transfected cells as compared with control untransfected cells in normoxia. Because the MYPT1 ( -LZ) construct lacks the leucine zipper, PKG was unable to bind and phosphorylate it at Ser 695 (Fig. 6a and c) . There was a two-fold increase in the relative ratio of pMLC 20 / MLC 20 in MYPT1 ( -LZ)-transfected cells as compared with untransfected cells (Fig. 6a and d (Fig. 6a and d) between mocktransfected cells and untransfected cells ( Fig. 6a and d) .
These results indicate that the LZ domain of MYPT1 is important for PKG-mediated phosphorylation (Ser 695 ) of MYPT1, which subsequently activates MLCP, leading to dephosphorylation of pMLC 20 , a step required for smooth muscle cell relaxation.
Hypoxia increases the interaction between RhoA or ROCK and LZ + MYPT1, and overexpression of MYPT1 ( -LZ) mimics hypoxia
To determine the interaction between RhoA or ROCK and LZ + MYPT1 in hypoxia, FPASMC were exposed to normoxia or hypoxia for 4 h, cell lysates prepared and immunoprecipitated with anti-PKG, anti-RhoA, anti-ROCK1 or anti-ROCK2 antibodies and then Western blotted with LZ + MYPT1 antibodies. There was a twofold increase in the interaction between LZ + MYPT1 and RhoA or ROCK1/ROCK2 and decreased LZ + MYPT1 interaction with PKG in FPASMC exposed to hypoxia (Fig. 7) . In MYPT1 ( -LZ) overexpressing FPASMC, there was a signi icant decrease in interaction between PKG and LZ + MYPT1 (Fig. 8a and b) , whereas an increase (~two to four-fold) in interaction between LZ + MYPT1 and RhoA, or ROCK1/ ROCK2, was observed ( Fig. 8c-f ). In cells transfected with MYPT1 ( + LZ) expression vector, there was enhanced (~2.5-fold) interaction between PKG and LZ + MYPT1 (Fig. 8a and b) , accompanied by decreased levels of MYPT1 ( + LZ) interaction with RhoA or ROCK1/ ROCK2 (Fig. 8c-f ).
DISCUSSION
Our data show that acute hypoxia downregulates the expression levels of LZ + MYPT1 by reducing PKG expression, decreases the interaction of LZ + MYPT1 with PKG and promotes its interaction with ROCK1/ROCK2 in ovine FPASMC. These changes are accompanied by a decreased ratio of pMLC 20 /MLC 20 ,indicative of increased smooth muscle contraction. Possible explanations for the change in binding af inity of PKG with LZ + MYPT1 in acute hypoxia may be: (1) differential downregulation of PKG and LZ + MYPT1, (2) increased af inity of RhoA, compared with PKG, to bind with LZ + MYPT1; and/or (3) posttranscriptional modi ication of PKG such that its af inity to bind with the LZ domain of MYPT1 is decreased. The irst two possibilities were examined by studying the effects of MYPT1 (LZ + ) or MYPT1 ( -LZ) overexpression on hypoxia-induced effects in SMC. Overexpression of LZ + MYPT1 or its known upstream activator, PKG, reversed hypoxia-induced effects, whereas LZ -MYPT1 overexpression mimicked the effects of hypoxia. Based on these observations and those from our earlier studies, [13, 15, 16] we propose that hypoxia causes the downregulation of PKG expression, thereby leading to reduced LZ + MYPT1 expression (see schematic, (Fig. 9) ). This leads to suppression of PKG binding to LZ domain of MYTP1, decreased phosphorylation of MYPT1 at Ser 695 and the inactivated state of MLCP. Lack of MLCP activation results in increased levels of pMLC 20 and contraction of SMC.
Previous studies have shown that ROS generated by hypoxia [17] [18] [19] [20] may be responsible for both decreased PKG and LZ + MYPT1 expression. Our studies show that ROS modulates LZ + MYPT1 expression indirectly through modulation of PKG protein and activity levels. Although we found that hypoxia downregulates PKG expression in a ROS-dependent manner, PKG overexpression alone restored the levels of MYPT1 ( + LZ) in cells exposed to hypoxia, and ROS scavengers failed to restore the expression levels of LZ + MYPT1 in PKG-de icient (knockdown) cells. These results suggest that hypoxia downregulates LZ + MYPT1 expression by reducing PKG levels through ROS, and not directly through ROSmediated effects. Furthermore, our data also suggest that PKG-mediated activation of MLCP is required for the expression of LZ + MYPT1, as overexpression of MYPT ( -LZ) mimics the effects of acute hypoxia on the expression of endogenous LZ + MYPT1.
SMC contractility is modulated by the ratio of phosphorylated MLC 20 to unphosphorylated MLC 20 (pMLC 20 /MLC 20 ) , and this ratio is regulated by the relative activities of MLCK/MLCP. [3, 4] Activation and inactivation of MLCP depends on the ratio of site-speci ic phosphorylation of MYPT1 (Ser 695 ) to unphosphorylated MYPT1 (pMYPT1 Ser 695/ MYPT1). In our study, hypoxia increased the pMLC 20 /MLC 20 ratio, as expected. Increased pMYPT1/MYPT1 ratio and MYPT1 ( + LZ) and PKG expression were associated with increased MLCP activity and smooth muscle relaxation in normoxia. Our data also showed that hypoxia decreases the interaction of PKG with MYPT1 and increases the interaction between LZ + MYPT1 and ROCK1/ROCK2. Surks et al. irst reported that the binding of PKG to MYPT1 is mediated by the LZ + motifs located at the N-and C-termini of the two proteins, respectively. [21] However, others have reported that the LZ + motif of MYPT1 is not required for the binding of PKG to MYPT1. [22] Another group [23] used multiple biophysical techniques to fully characterize the interaction of the C-terminal region of MYPT1 with the N-terminal LZ + motif of PKG. Their data showed that under physiological conditions, the LZ + motif of PKG binds to the LZ + motif of MYPT1 to form a heterodimer. When the LZ + motif of MYPT1 is absent, the PKG LZ + binds to the coiled-coil region and upstream segments of MYPT1 with the formation of a heterotetramer; however, there is no phosphorylation at Ser 695 and no activation of MLCP. [22] Regulation of expression levels of MYPT1 ( + LZ) via the NO-cGMP-PKG pathway plays a key role in smooth muscle relaxation under a number of physiological and pathophysiological conditions. [14] For instance, in rats between postnatal days 6 and 12, expression of MYPT1 in portal veins switches from LZ (+) to LZ (-) isoforms, [11] which is concordant with a switch from cGMP-sensitive vascular relaxation to insensitivity to cGMP. [11, 21, 24, 25] In the rat model of congestive heart failure, decreased relaxation of the aorta is associated with decreased expression of MYPT1 ( + LZ). [7, 24, 26] Earlier studies have shown that continuous exposure of pulmonary vessels to nitric oxide leads to NO tolerance with decreased cGMP-induced PKG activity. [27, 28] In these studies, it was reported that increased accumulation of cGMP led to downregulation of PKG protein expression and activity in a negative feedback manner. A similar study demonstrated that a reduction in MYPT1 ( + LZ) expression, downstream of the NO-cGMP-PKG pathway, is involved in the development of NO tolerance and that this process is in part due to proteasome-dependent degradation of LZ + MYPT1. [27, 29] Earlier studies have also shown that preservation of MYPT1 ( + LZ) expression could prevent the decrease in cGMP-mediated vasodilatation in chronic heart failure. [24, 26] 
CONCLUSIONS
In summary, data presented in this study support our hypothesis that hypoxia stimulates multiple signaling pathways that act in a concerted manner to regulate SMC contraction. MYPT1 subunit of MLCP is the key regulatory protein in SMC contraction and relaxation, and dysfunctional MYPT1 signaling can contribute to the pathophysiology of a number of diseases;e.g., hypertension, gastrointestinal dysmotility, vasospasm and congestive heart failure. [7, [30] [31] [32] Thus, we propose that strategies to restore MYPT1 ( + LZ) expression, by selective inhibition of MYPT1 ( + LZ) degradation and/or over expression of PKG or MYPT1 ( + LZ), may provide a promising approach for the treatment of diseases linked to SMC dysfunction.
